Ozempic ingredient slows biological aging in human trial
New clinical trials show semaglutide can slow biological aging markers, a finding that could significantly expand the already massive market for GLP-1 drugs produced by European pharmaceutical manufacturers.
Semaglutide, the active compound in widely prescribed weight-loss drugs Ozempic and Wegovy, has been shown to slow biological aging in humans for the first time. A randomized, placebo-controlled trial published in Nature Communications found that weekly injections of the medication reduced the pace of molecular aging by 9% compared to a placebo.
For European investors and health systems, these findings hint at a new frontier for GLP-1 receptor agonists. The market for these drugs, heavily anchored by European manufacturers, has already expanded massively due to their effectiveness against obesity and cardiovascular disease. Evidence that they might also extend a patient's healthy years could further drive long-term demand and reshape how the continent manages chronic disease.
Researchers at the University of California San Diego evaluated 108 adults with HIV-associated lipohypertrophy, a condition characterized by excess abdominal fat. People with HIV often experience accelerated biological aging even when the virus is controlled. Using "epigenetic clocks" that measure DNA methylation to estimate biological age, the team found semaglutide outperformed the placebo across multiple organ systems, including the heart, liver, and kidneys.
The drug appears to combat aging by reducing inflammation and clearing visceral and ectopic fat deposits that drive chronic immune activation. "Emerging data also suggest that GLP-1 drugs may reprogram certain cells in different organs, which could help explain why we see effects across multiple aging clocks," said Michael Corley, the study's first author.
A related pilot study published last month in npj Aging supports these conclusions. In that 24-week trial involving patients with fatty liver disease, 42% of participants saw slower aging, while 34% showed slowed aging processes tied to all-cause mortality. Furthermore, nearly half exhibited longer telomeres, the protective caps on chromosomes, and those individuals tended to walk faster after treatment.
Scientists caution that semaglutide should not be classified as an anti-aging drug yet. "We are not saying that semaglutide reverses aging or makes people younger," Corley said. "What we are seeing is a signal that it may slow some of the biological processes associated with aging." Much larger clinical trials are still needed to confirm the results and determine if the general population experiences the same benefits.
